#USA #San Francisco #Biopharma #ixlayer #Helmut Osorio

ixlayer Appoints Helmut Osorio as General Manager

In a strategic move to bolster its direct-to-patient (DTP) initiatives, ixlayer has appointed Helmut Osorio as the new General Manager. This news comes during a transformative phase for both ixlayer and the DTP healthcare sector as a whole. With over 20 years of extensive experience in marketing and product launches at leading pharmaceutical companies, Osorio's appointment is expected to drive innovative engagement strategies for patients and streamline their healthcare journey.

Significance of the Appointment

The direct-to-patient model is increasingly essential for pharmaceutical companies, particularly in a landscape where audiences are saturated with information but often lack clarity on how to proceed with their treatment options. ixlayer has made significant strides in providing an effective DTP template that connects patients with necessary healthcare solutions. By bringing Osorio on board, the company aims to capitalize on this momentum and address the evolving needs of the market.

As Healthcare Technology Innovation of the Year award recipient, ixlayer's cutting-edge platform enhances how patients access treatments. It serves not only as a marketing tool but also as an integral part of patient care, improving health equity and outcomes for users. With more than six awards earned recently, the company demonstrates its vision for forward-thinking healthcare solutions, alongside Osorio's expertise in efficiently bridging the gap between awareness and action in treatment processes.

Background of Helmut Osorio

Osorio previously held notable positions, including Senior Director of Marketing for Ophthalmology at Regeneron Pharmaceuticals, where he successfully led product strategies for the widely used drug EYLEA HD. His experience also extends to advising biopharmaceutical companies as a Principal at Gordian Solutions LLC, where he focused on commercialization and market access strategies.

His career trajectory includes senior roles at Purdue Pharma, Auxilium Pharmaceuticals, and Pfizer, where he honed his skills in brand strategy and access planning. With such a wealth of experience, especially in primary and specialty care segments, Osorio is well-positioned to enhance ixlayer's collaborations with biopharma partners.

Industry Demand and Future Directions

The need for effective DTP models has never been more pressing, as a recent survey by ixlayer in collaboration with the Digital Health Coalition indicated that a staggering 94% of pharmaceutical leaders are either currently utilizing or planning to implement a DTP program. Furthermore, an alarming 82% of respondents noted that fragmented healthcare experiences have compromised the effectiveness of their direct-to-consumer spending.

Pouria Sanae, co-founder and CEO of ixlayer, emphasized the urgent need for pharmaceutical marketers to not only drive awareness but to translate that awareness into actionable, measurable patient outcomes. In his view, the most successful brands in today's landscape will be those who can strategically use their DTC expenditures to yield tangible health improvements for patients.

With Osorio's insights and leadership, ixlayer looks to seize this opportunity, helping biopharma partners navigate the complexities of patient engagement and care progression effectively.

Conclusion

Osorio's dual graduate degrees in Marketing and Finance from the University of Michigan and his bilingual fluency in English and Spanish enhance his potential to connect with diverse patient populations. As ixlayer moves forward with its innovative technologies and patient-centric platforms, the involvement of a seasoned professional like Osorio promises to advance their mission of improving healthcare accessibility and equity.

In a market that increasingly demands direct, personal engagement, ixlayer under Osorio's leadership is set to redefine how patients experience healthcare delivery, ultimately closing the gap between pharmaceutical awareness and tangible patient action.